Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2343]

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II...

Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA

MERMAID-2: Phase 3 study of durvalumab in patients with resected stage MRD II-III NSCLC ( Dr David Spigel - Sarah Cannon Research Institute, Nashville, USA )

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small...

Dr Erminia Massarelli - City of Hope, Duarte, USA

Autologous tumour infiltrating lymphocytes cell therapy in metastatic non-small cell lung cancer ( Dr Erminia Massarelli - City of Hope, Duarte, USA )

Incorporating KRAS as a novel biomarker: Challenges and opportunities

Prof Ales Ryska - Charles University, Prague, Czech Republic

Incorporating KRAS as a novel biomarker: Challenges and opportunities ( Prof Ales Ryska - Charles University, Prague, Czech Republic )

Real world data and diagnostics in patients with NSCLC with EGFR exon 20...

Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio...

Real world data and diagnostics in patients with NSCLC with EGFR exon 20 insertions ( Prof Nicolas Girard, Prof Keith Kerr, Prof Frank Griesinger and Dr Antonio Passaro )

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC...

Prof Andrea Filippi - University of Pavia, Pavia, Italy

Durvalumab following radiotherapy in patients with unresectable, stage 3 NSCLC ineligible for chemotherapy ( Prof Andrea Filippi - University of Pavia, Pavia, Italy )

Promise of personalised medicine for patients with prostate cancer

Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt...

Promise of personalised medicine for patients with prostate cancer ( Prof Eleni Efstathiou, Prof Alicia Morgans, Prof Karim Fizazi and Prof Gerhardt Attard )

Long term response to apalutamide and other updates impacting patients with...

Prof Axel Merseburger and Prof Matthew Smith

Long term response to apalutamide and other updates impacting patients with nmCRPC from ASCO GU 2021 ( Prof Axel Merseburger and Prof Matthew Smith )

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early...

Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt...

mCRPC and nmCRPC: Combinations and latest data, what does COVID mean for early treatment? ( Dr Eleni Efstathiou, Prof Stefan Oudard Prof Boris Hadaschik and Prof Gerhardt Attard )

Diagnosis, testing and biomarkers in the individualisation of patient care with...

Prof Andrea Necchi and Prof Eva Compérat

Diagnosis, testing and biomarkers in the individualisation of patient care with FGFR mutated bladder cancer ( Prof Andrea Necchi and Prof Eva Compérat )

Neo-adjuvant therapy and surgical decision making in breast cancer

Dr Mehra Golshan - Yale School of Medicine, New Haven, USA

Neo-adjuvant therapy and surgical decision making in breast cancer ( Dr Mehra Golshan - Yale School of Medicine, New Haven, USA )

Nurse's perspective on PARP inhibitors and personalised medicine in prostate...

Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK

Nurse's perspective on PARP inhibitors and personalised medicine in prostate cancer ( Louisa Fleure - Guy's and St Thomas' NHS Trust, London, UK )

COVID-19 pandemic threatens global life-saving gains in childhood cancer

Prof Kathy Pritchard-Jones - University College London, London, UK

COVID-19 pandemic threatens global life-saving gains in childhood cancer ( Prof Kathy Pritchard-Jones - University College London, London, UK )

More from ecancer